Investigating the mechanisms of hallucinogen-induced visions using 3,4-methylenedioxyamphetamine (MDA): A randomized controlled trial in humans

PLoS ONE

Volumn 5, Issue 12, 2010, Pages

  Baggott, Matthew J ^a   Siegrist, Jennifer D ^a   Galloway, Gantt P ^a   Robertson, Lynn C ^b,c   Coyle, Jeremy R ^a   Mendelson, John E ^a  

^a CALIFORNIA PACIFIC MEDICAL CENTER   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3,4 METHYLENEDIOXYAMPHETAMINE; PLACEBO; PSYCHEDELIC AGENT; AMINE; SEROTONIN 2 AGONIST;

ABNORMAL VISION; ADULT; ADVERSE OUTCOME; ARTICLE; BRAIN DEPTH STIMULATION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG DOSE SEQUENCE; DRUG EFFECT; DRUG HALF LIFE; DRUG TOLERABILITY; EUPHORIA; FEAR; FEMALE; HUMAN; HUMAN EXPERIMENT; MALE; MENTAL INSTABILITY; MYSTICISM; NORMAL HUMAN; OCCIPITAL CORTEX; PERCEPTION DISORDER; PERSONAL EXPERIENCE; PREDICTION; RANDOMIZED CONTROLLED TRIAL; SELF REPORT; SIDE EFFECT; TASK PERFORMANCE; VISUAL ACUITY; VISUAL DISCRIMINATION; VISUAL HALLUCINATION; VISUAL ILLUSION; VISUAL MEMORY; VISUAL STIMULATION; VISUAL THRESHOLD; CHEMISTRY; HALLUCINATION; PSYCHOLOGICAL ASPECT; QUESTIONNAIRE; VISION;

3,4-METHYLENEDIOXYAMPHETAMINE; ADULT; AMINES; CROSS-OVER STUDIES; HALLUCINATIONS; HALLUCINOGENS; HUMANS; MALE; PLACEBOS; QUESTIONNAIRES; SEROTONIN 5-HT2 RECEPTOR AGONISTS; VISION, OCULAR; VISUAL PERCEPTION;

EID: 78649955028     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0014074     Document Type: Article

References (122)

1. Shanon B (2002) The antipodes of the mind: charting the phenomenology of the ayahuasca experience: Oxford University Press, USA.
2. Klüver H (1966) Mescal and mechanisms of hallucinations. ChicagoIL: University of Chicago Press.
3. Shulgin A, Shulgin A (1991) Pihkal: A chemical love story. Berkeley, CA: Transform Press. 978 plus introductory pages p.
4. Shulgin A, Shulgin A (1997) Tihkal: The Continuation. Berkeley, CA: Transform Press.
5. West L, ed (1962) Hallucinations. New York: Grune & Stratton.
6. Hollister LE (1968) Chemical Psychoses: LSD and Related Drugs. Springfield, IL: Charles C. Thomas.
7. Hoffer A (1965) D-Lysergic acid diethylamide (LSD): A review of its present status. Clinical pharmacology and therapeutics 6:183-255.
8. Lebovits B, Visotsky H, Ostfeld A (1960) LSD and JB 318: A comparison of two hallucinogens. Arch Gen Psychiat 2: 390.
9. Hollister LE, Hartman AM (1962) Mescaline, lysergic acid diethylamide and psilocybin comparison of clinical syndromes, effects on color perception and biochemical measures. Compr Psychiatry 3:235-242.
10. Bercel NA, Travis LE, Olinger LB, Dreikurs E (1956) Model psychoses induced by LSD-25 in normals. I. Psychophysiological investigations, with special reference to the mechanism of the paranoid reaction. AMA Arch Neurol Psychiatry 75:588-611.
11. Schwarz B, Bickford R, Rome H (1955) Reversibility of induced psychosis with chlorpromazine. 407 p.
12. Mayer-Gross W, Stein H (1926) U ̈ ber einige abänderungen der sinnestä tigkeit im Meskalinrausch. Zeitschrift für die gesamte Neurologie und Psychiatrie 101:354-386.
13. Hartman AM, Hollister LE (1963) Effect of Mescaline, Lysergic Acid Diethylamide and Psilocybin on Color Perception. Psychopharmacologia 4:441-451.
14. Keeler MH (1965) The effects of psilocybin on a test of after-image perception. Psychopharmacologia 8:131-139.
15. Knauer A, Maloney W (1913) A preliminary note on the psychic action of mescalin, with special reference to the mechanism of visual hallucinations. J Nerv Ment Dis 40: 425.
16. Cohen S (1971) The psychotomimetic agents. In: Junger E, ed. Progress in Drug Research. 1967/01/01 ed. Basel & Stuttgart, Birkhauser Verlag. pp68-102.
17. Carter OL, Pettigrew JD, Burr DC, Alais D, Hasler F, et al. (2004) Psilocybin impairs high-level but not low-level motion perception. Neuroreport 15:1947-1951.
18. Nichols DE (1986) Differences between the mechanism of action of MDMA, MBDB, and the classic hallucinogens. Identification of a new therapeutic class: entactogens. J Psychoactive Drugs 18:305-313.
19. Lyon RA, Glennon RA, Titeler M (1986) 3,4-Methylenedioxymethamphetamine (MDMA): stereoselective interactions at brain 5-HT1 and 5-HT2 receptors. Psychopharmacology (Berl) 88:525-526.
20. Paton DM, Bell JI, Yee R, Cook DA (1975) Pharmacology and toxicity of 3,4- methylenedioxyamphetamine, para- methoxyamphetamine and related dimethoxyamphetamines. Proc West Pharmacol Soc 18:229-231.
21. Bexis S, Docherty JR (2006) Effects of MDMA, MDA and MDEA on blood pressure, heart rate, locomotor activity and body temperature in the rat involve alpha-adrenoceptors. Br J Pharmacol 147:926-934.
22. Baumann MH, Wang X, Rothman RB (2007) 3,4-Methylenedioxymethamphetamine (MDMA) neurotoxicity in rats: a reappraisal of past and present findings. Psychopharmacology (Berl) 189:407-424.
23. Baggott M, Heifets B, Jones RT, Mendelson J, Sferios E, et al. (2000) Chemical analysis of ecstasy pills. JAMA 284: 2190.
24. Camilleri AM, Caldicott D (2005) Underground pill testing, down under. Forensic Sci Int 151:53-58.
25. Pentney AR (2001) An exploration of the history and controversies surrounding MDMA and MDA. J Psychoactive Drugs 33:213-221.
26. Naranjo C (1973) The healing journey: new approaches to consciousness. New York: Pantheon Books.
27. Yensen R, Di Leo FB, Rhead JC, Richards WA, Soskin RA, et al. (1976) MDA-assisted psychotherapy with neurotic outpatients: a pilot study. J Nerv Ment Dis 163:233-245.
28. Anderson G, Braun G, Braun U, Nichols DE, Shulgin AT (1978) Absolute configuration and psychotomimetic activity. In: Barnett G, Trsic M, Willette R, eds. Quantitative Structure Activity Relationships of Analgesics, Narcotic Antagonists, and Hallucinogens, NIDA Research Monograph 22. Washington, DC: US Government Printing Office. pp8-15.
29. Braun U, Shulgin AT, Braun G (1980) Centrally active N-substituted analogs of 3,4-methylenedioxyphenylisopropylamine (3,4-methylenedioxyamphetamine). J Pharm Sci 69:192-195.
30. Weil A (1976) The love drug. J Psychedelic Drugs 8: 335.
31. Baker LE, Taylor MM (1997) Assessment of the MDA and MDMA optical isomers in a stimulant- hallucinogen discrimination. Pharmacol Biochem Behav 57:737-748.
32. Young R, Glennon RA (1996) A three-lever operant procedure differentiates the stimulus effects of R(-)-MDA from S(+)-MDA. J Pharmacol Exp Ther 276:594-601.
33. O'Hearn E, Battaglia G, De Souza EB, Kuhar MJ, Molliver ME (1988) Methylenedioxyamphetamine (MDA) and methylenedioxymethamphetamine (MDMA) cause selective ablation of serotonergic axon terminals in forebrain: immunocytochemical evidence for neurotoxicity. J Neurosci 8:2788-2803.
34. Fletcher PC, Frith CD (2009) Perceiving is believing: a Bayesian approach to explaining the positive symptoms of schizophrenia. Nat Rev Neurosci 10:48-58.
35. Ffytche DH (2008) The hodology of hallucinations. Cortex 44:1067-1083.
36. Collerton D, Perry E, McKeith I (2005) Why people see things that are not there: a novel Perception and Attention Deficit model for recurrent complex visual hallucinations. Behav Brain Sci 28: 737-757; discussion757-794.
37. Behrendt RP, Young C (2004) Hallucinations in schizophrenia, sensory impairment, and brain disease: a unifying model. Behav Brain Sci 27: 771-787; discussion787-830.
38. Manford M, Andermann F (1998) Complex visual hallucinations. Clinical and neurobiological insights. Brain 121(Pt 10):1819-1840.
39. Asaad G, Shapiro B (1986) Hallucinations: theoretical and clinical overview. Am J Psychiatry 143:1088-1097.
40. Ffytche DH (2009) Visual hallucinations in eye disease. Curr Opin Neurol 22:28-35.
41. Pieri V, Diederich NJ, Raman R, Goetz CG (2000) Decreased color discrimination and contrast sensitivity in Parkinson's disease. J Neurol Sci 172:7-11.
42. Diederich NJ, Goetz CG, Raman R, Pappert EJ, Leurgans S, et al. (1998) Poor visual discrimination and visual hallucinations in Parkinson's disease. Clin Neuropharmacol 21:289-295.
43. Biousse V, Skibell BC, Watts RL, Loupe DN, Drews-Botsch C, et al. (2004) Ophthalmologic features of Parkinson's disease. Neurology 62:177-180.
44. Buttner T, Kuhn W, Muller T, Welter FL, Federlein J, et al. (1996) Visual hallucinosis: the major clinical determinant of distorted chromatic contour perception in Parkinson's disease. J Neural Transm 103:1195-1204.
45. Ramirez-Ruiz B, Junque C, Marti MJ, Valldeoriola F, Tolosa E (2006) Neuropsychological deficits in Parkinson's disease patients with visual hallucinations. Mov Disord 21:1483-1487.
46. Ramirez-Ruiz B, Junque C, Marti MJ, Valldeoriola F, Tolosa E (2007) Cognitive changes in Parkinson's disease patients with visual hallucinations. Dement Geriatr Cogn Disord 23:281-288.
47. Barnes J, Boubert L, Harris J, Lee A, David AS (2003) Reality monitoring and visual hallucinations in Parkinson's disease. Neuropsychologia 41:565-574.
48. Gabrovska V, Laws K, Sinclair J, McKenna P (2003) Visual object processing in schizophrenia: evidence for an associative agnosic deficit. Schizophrenia research 59:277-286.
49. Silverstein S, Uhlhaas PJ, Essex B, Halpin S, Schall U, et al. (2006) Perceptual organization in first episode schizophrenia and ultra-high-risk states. Schizophr Res 83:41-52.
50. Silverstein SM, Hatashita-Wong M, Schenkel LS, Wilkniss S, Kovacs I, et al. (2006) Reduced top-down influences in contour detection in schizophrenia. Cogn Neuropsychiatry 11:112-132.
51. Keri S, Kelemen O, Benedek G (2009) Attentional modulation of perceptual organisation in schizophrenia. Cogn Neuropsychiatry 14:77-86.
52. Koethe D, Gerth CW, Neatby MA, Haensel A, Thies M, et al. (2006) Disturbances of visual information processing in early states of psychosis and experimental delta-9-tetrahydrocannabinol altered states of consciousness. Schizophr Res 88:142-150.
53. Silverstein SM, Berten S, Essex B, Kovacs I, Susmaras T, et al. (2009) An fMRI examination of visual integration in schizophrenia. J Integr Neurosci 8:175-202.
54. Uhlhaas PJ, Phillips WA, Mitchell G, Silverstein SM (2006) Perceptual grouping in disorganized schizophrenia. Psychiatry Res 145:105-117.
55. Uhlhaas PJ, Millard I, Muetzelfeldt L, Curran HV, Morgan CJ (2007) Perceptual organization in ketamine users: preliminary evidence of deficits on night of drug use but not 3 days later. J Psychopharmacol 21:347-352.
56. Elliott B, Joyce E, Shorvon S (2009) Delusions, illusions and hallucinations in epilepsy: 2. Complex phenomena and psychosis. Epilepsy Res 85:172-186.
57. Elliott B, Joyce E, Shorvon S (2009) Delusions, illusions and hallucinations in epilepsy: 1. Elementary phenomena. Epilepsy Res 85:162-171.
58. Leao A (1944) Spreading depression of activity in the cerebral cortex. J neurophysiol 7:359-390.
59. Lauritzen M (2001) Cortical spreading depression in migraine. Cephalalgia 21:757-760.
60. Levine DN, Finklestein S (1982) Delayed psychosis after right temporoparietal stroke or trauma: relation to epilepsy. Neurology 32:267-273.
61. Noda S, Mizoguchi M, Yamamoto A (1993) Thalamic experiential hallucinosis. J Neurol Neurosurg Psychiatry 56:1224-1226.
62. Penfield W, Perot P (1963) The Brain's Record of Auditory and Visual Experience. a Final Summary and Discussion. Brain 86:595-696.
63. Ermentrout GB, Cowan JD (1979) A mathematical theory of visual hallucination patterns. Biol Cybern 34:137-150.
64. Aghajanian GK (2009) Modeling ''psychosis'' in vitro by inducing disordered neuronal network activity in cortical brain slices. Psychopharmacology (Berl) 206:575-585.
65. Gonzalez-Maeso J, Sealfon SC (2009) Agonist-trafficking and hallucinogens. Curr Med Chem 16:1017-1027.
66. Geyer MA, Vollenweider FX (2008) Serotonin research: contributions to understanding psychoses. Trends Pharmacol Sci.
67. Nichols DE (2004) Hallucinogens. Pharmacol Ther 101:131-181.
68. Winter JC (2009) Hallucinogens as discriminative stimuli in animals: LSD, phenethylamines, and tryptamines. Psychopharmacology (Berl) 203:251-263.
69. Baker TI, Cowan JD (2009) Spontaneous pattern formation and pinning in the primary visual cortex. J Physiol Paris 103:52-68.
70. Bressloff PC, Cowan JD, Golubitsky M, Thomas PJ, Wiener MC (2002) What geometric visual hallucinations tell us about the visual cortex. Neural Comput 14:473-491.
71. Billock VA, Tsou BH (2007) Neural interactions between flicker-induced selforganized visual hallucinations and physical stimuli. Proc Natl Acad Sci U S A 104:8490-8495.
72. Corlett PR, Frith CD, Fletcher PC (2009) From drugs to deprivation: a Bayesian framework for understanding models of psychosis. Psychopharmacology (Berl).
73. Hirshman E, Snodgrass J, Mindes J, Feenan K (1990) Conceptual priming in fragment completion. Journal of Experimental Psychology: Learning, Memory, and Cognition 16:634-647.
74. Snodgrass J, Feenan K (1990) Priming effects in picture fragment completion: Support for the perceptual closure hypothesis. Journal of Experimental Psychology: General 119:276-296.
75. Sadr J, Sinha P (2004) Object recognition and random image structure evolution. Cognitive Science 28:259-287.
76. Bar M (2003) A cortical mechanism for triggering top-down facilitation in visual object recognition. Journal of Cognitive Neuroscience 15:600-609.
77. Bar M, Kassam K, Ghuman A, Boshyan J, Schmid A, et al. (2006) Top-down facilitation of visual recognition. Proceedings of the National Academy of Sciences 103: 449.
78. Palmer S (1975) The effects of contextual scenes on the identification of objects. Memory and Cognition 3:519-526.
79. Griffiths RR, Richards WA, McCann U, Jesse R (2006) Psilocybin can occasion mystical-type experiences having substantial and sustained personal meaning and spiritual significance. Psychopharmacology (Berl) 187: 268-283; discussion284-292.
80. Dittrich A (1998) The standardized psychometric assessment of altered states of consciousness (ASCs) in humans. Pharmacopsychiatry 31(Suppl 2):80-84.
81. Dittrich A (1994) Psychological aspects of altered states of consciousness of the LSD type: measurements of their basic dimensions and prediction of individual differences. In: Pletscher A, Ladewig D, eds. Fifty Years of LSD: Current Status and Perspectives of Hallucinogens. New York: Parthenon. pp101-118.
82. Hood RW, Jr. (1975) The construction and preliminary validation of a measure of reported mystical experience. Journal for the Scientific Study of Religion 14:29-41.
83. Stace W (1960) Mysticism and philosophy. Philadelphia: Lippincott.
84. Hood RW, Ghorbani N, Watson PJ, Ghramaleki AF, Bing MN, et al. (2001) Dimensions of the Mysticism Scale: Confirming the Three-Factor Structure in the United States and Iran. J Sci Study Relig 40:691-705.
85. Reinert D, Stifler K (1993) Hood's mysticism scale revisited: A factor-analytic replication. Journal for the scientific study of religion 32:383-388.
86. Calvert JE, Harris JP (1988) Spatial frequency and duration effects on the tilt illusion and orientation acuity. Vision Res 28:1051-1059.
87. Schwartz O, Hsu A, Dayan P (2007) Space and time in visual context. Nat Rev Neurosci 8:522-535.
88. Carpenter RH, Blakemore C (1973) Interactions between orientations in human vision. Exp Brain Res 18:287-303.
89. Wenderoth P, Johnstone S (1988) The different mechanisms of the direct and indirect tilt illusions. Vision Res 28:301-312.
90. Jin DZ, Dragoi V, Sur M, Seung HS (2005) Tilt aftereffect and adaptationinduced changes in orientation tuning in visual cortex. J Neurophysiol 94:4038-4050.
91. Kohn A (2007) Visual adaptation: physiology, mechanisms, and functional benefits. J Neurophysiol 97:3155-3164.
92. Kohn A, Movshon JA (2004) Adaptation changes the direction tuning of macaque MT neurons. Nat Neurosci 7:764-772.
93. Teich AF, Qian N (2003) Learning and adaptation in a recurrent model of V1 orientation selectivity. J Neurophysiol 89:2086-2100.
94. Schwartz O, Sejnowski TJ, Dayan P (2009) Perceptual organization in the tilt illusion. J Vis 9: 1911-20.
95. Bressloff PC, Cowan JD (2002) An amplitude equation approach to contextual effects in visual cortex. Neural Comput 14:493-525.
96. Yang CPI (2003) A new angle on the tilt illusion. ChicagoIL: University of Chicago.
97. Chandna A, Pennefather PM, Kovacs I, Norcia AM (2001) Contour integration deficits in anisometropic amblyopia. Invest Ophthalmol Vis Sci 42:875-878.
98. Kiorpes L, Bassin SA (2003) Development of contour integration in macaque monkeys. Vis Neurosci 20:567-575.
99. Kourtzi Z, Tolias AS, Altmann CF, Augath M, Logothetis NK (2003) Integration of local features into global shapes: monkey and human FMRI studies. Neuron 37:333-346.
100. Knoblauch K (2008) psyphy: Functions for analyzing psychophysical data in R. R package version 0.0-9 ed.
101. Rossion B, Pourtois G (2004) Revisiting Snodgrass and Vanderwart's object pictorial set: the role of surface detail in basic-level object recognition. Perception 33:217-236.
102. Torralba A, Oliva A (2003) Statistics of natural image categories. Network: computation in neural systems 14:391-412.
103. R Development Core Team (2007) R: A language and environment for statistical computing. Vienna, Austria: R Foundation for Statistical Computing.
104. Jaffe JH (1990) Drug Addiction and Drug Abuse. In: Gilman AG, Rail TW, Nies AS, Taylor P, eds. Goodman and Gilman's The Pharmacological Basis of Therapeutics. New York: Pergamon Press. pp522-573.
105. Griffiths R, Richards W, Johnson M, McCann U, Jesse R (2008) Mystical-type experiences occasioned by psilocybin mediate the attribution of personal meaning and spiritual significance 14 months later. J Psychopharmacol 22:621-632.
106. Alles GA (1959) Some Relations between Chemical Structive and Physiological Action of Mescaline and Related Compounds. In: Abramson HA, ed. Neuropharmacology. New York: Josiah Macey Jr. Foundation. pp181-268.
107. Naranjo C, Shulgin AT, Sargent T (1967) Evaluation of 3,4-methylenedioxyamphetamine (MDA) as an adjunct to psychotherapy. Med Pharmacol Exp Int J Exp Med 17:359-364.
108. Turek I, Soskin R, Kurland AA (1974) Methylendedioxyamphetamine (MDA) subjective effects. J Psychedelic Drugs 6:7-13.
109. Hollister LE, Sjoberg BM (1964) Clinical Syndromes and Biochemical Alterations Following Mescaline, Lysergic Acid Diethylamide, Psilocybin and A Combination of the Three Psychotomimetic Drugs. Comprehensive Psychiatry 5:170-178.
110. Collerton D, Burn D, McKeith I, O'Brien J (2003) Systematic review and meta-analysis show that dementia with Lewy bodies is a visual-perceptual and attentional-executive dementia. Dement Geriatr Cogn Disord 16:229-237.
111. Hadjikhani N, Sanchez Del Rio M, Wu O, Schwartz D, Bakker D, et al. (2001) Mechanisms of migraine aura revealed by functional MRI in human visual cortex. Proc Natl Acad Sci U S A 98:4687-4692.
112. Brown J, Edwards M, McKone E, Ward J (2007) A long-term ecstasy-related change in visual perception. Psychopharmacology (Berl) 193:437-446.
113. Dickson C, Bruno R, Brown J (2009) Investigating the role of serotonin in visual orientation processing using an 'ecstasy' (MDMA)-based research model. Neuropsychobiology 60:204-212.
114. Oliveri M, Calvo G (2003) Increased visual cortical excitability in ecstasy users: a transcranial magnetic stimulation study. J Neurol Neurosurg Psychiatry 74:1136-1138.
115. Cowan RL, Haga E, de BFB, Dietrich MS, Vimal RL, et al. (2006) MDMA use is associated with increased spatial BOLD fMRI visual cortex activation in human MDMA users. Pharmacol Biochem Behav 84:219-228.
116. Creighton FJ, Black DL, Hyde CE (1991) 'Ecstasy' psychosis and flashbacks. Br J Psychiatry 159:713-715.
117. McGuire P, Fahy T (1992) Flashbacks following MDMA. Br J Psychiatry 160: 276.
118. Posner MI, Snyder CR, Davidson BJ (1980) Attention and the detection of signals. J Exp Psychol 109:160-174.
119. Bennett PJ, Sekuler AB, Ozin L (1999) Effects of aging on calculation efficiency and equivalent noise. J Opt Soc Am A Opt Image Sci Vis 16:654-668.
120. Hayes RD, Merigan WH (2007) Mechanisms of Sensitivity Loss due to Visual Cortex Lesions in Humans and Macaques. Cereb Cortex 17:1117-1128.
121. Pelli DG, Farell B (1999) Why use noise? J Opt Soc Am A Opt Image Sci Vis 16:647-653.
122. Kersten D, Hess R, Plant G (1988) Assessing contrast sensitivity behind cloudy media. Clinical Vision Science 2:143-158.